Grufity logo
Grufity logo

Latest BAKER BROS. ADVISORS LP Stock Portfolio

$17.42Billion | No. of Holdings #83

Felix & Julian Baker Performance

2026 Q1-0.51%
YTD-0.51%
2025+61.07%

About Felix & Julian Baker and 13F Hedge Fund Stock Holdings

Felix & Julian Baker is a hedge fund based in New York, NY. On 2026-05-15, the fund reported it's updated stock portfolio. In the 13F Holdings report, Felix & Julian Baker reported an equity portfolio of $17.4 Billions as of 31 Mar, 2026. <br><br> The top stock holdings of Felix & Julian Baker are INCY, BGNE, INSM. The fund has invested 16.6% of it's portfolio in INCYTE CORPORATION and 15% of portfolio in BEONE MEDICINES LTD. <br><br> The fund managers got completely rid off ULTRAGENYX PHARMACEUTICAL INC. (RARE), TERNS PHARMACEUTICALS, INC. (TERN) and BIOCRYST PHARMACEUTICALS, INC. (BCRX) stocks. They significantly reduced their stock positions in IMMUNOCORE HOLDINGS PLC (IMCR), BIONTECH SE (BNTX) and TECTONIC THERAPEUTIC, INC.. Felix & Julian Baker opened new stock positions in MIRUM PHARMACEUTICALS, INC. (MIRM), EVOMMUNE, INC. and COMPASS PATHWAYS PLC (CMPS). The fund showed a lot of confidence in some stocks as they added substantially to ENLIVEN THERAPEUTICS, INC., WAVE LIFE SCIENCES LTD. (WVE) and PRAXIS PRECISION MEDICINES, INC. (PRAX).
Felix & Julian Baker Equity Portfolio Value
Last Reported on: 15 May, 2026
$17.42Billion
  as of May 15, 2026

Felix & Julian Baker Annual Return Estimates Vs S&P 500

Our best estimate is that BAKER BROS. ADVISORS LP made a return of -0.51% in the last quarter. In trailing 12 months, it's portfolio return was 63.54%.
  • Performance
  • S&P 500

New Buys

Ticker$ Bought
mirum pharmaceuticals, inc.41,199,200
evommune, inc.19,481,500
aktis oncology, inc.17,824,700
generate biomedicines, inc.17,795,000
compass pathways plc12,966,300
eikon therapeutics, inc.5,877,770
verastem, inc.3,099,210
New stocks bought by BAKER BROS. ADVISORS LP

Additions

Ticker% Inc.
enliven therapeutics, inc.233
wave life sciences ltd.139
grail, inc.93.19
praxis precision medicines, inc.55.63
arcus biosciences, inc.53.93
crinetics pharmaceuticals, inc.42.61
alumis inc.28.8
cytomx therapeutics, inc.17.06
Additions to existing portfolio by BAKER BROS. ADVISORS LP

Reductions

Ticker% Reduced
immunocore holdings plc-68.38
biontech se-67.54
tectonic therapeutic, inc.-32.72
roivant sciences ltd.-12.37
immatics n.v.-9.74
arrowhead pharmaceuticals, inc.-8.4
BAKER BROS. ADVISORS LP reduced stake in above stock

Sold off

Ticker$ Sold
biocryst pharmaceuticals, inc.-22,017,300
ultragenyx pharmaceutical inc.-63,771,900
ventyx biosciences, inc.-21,214,000
terns pharmaceuticals, inc.-38,380,000
vir biotechnology, inc.-3,271,510
4d molecular therapeutics, inc.-3,568,030
nuvalent, inc.-14,478,600
kala bio, inc.-1,002,870
BAKER BROS. ADVISORS LP got rid off the above stocks

Sector Distribution

BAKER BROS. ADVISORS LP has about 93.9% of it's holdings in Healthcare sector.

  • Healthcare
  • Others
Sector%
Healthcare93.9
Others6.1

Market Cap. Distribution

BAKER BROS. ADVISORS LP has about 56.3% of it's portfolio invested in the large-cap and mega-cap stocks.

  • LARGE-CAP
  • MID-CAP
  • MEGA-CAP
  • SMALL-CAP
  • UNALLOCATED
Category%
LARGE-CAP41.2
MID-CAP28.7
MEGA-CAP15.1
SMALL-CAP8.6
UNALLOCATED6.1

Stocks belong to which Index?

About 71.8% of the stocks held by BAKER BROS. ADVISORS LP either belong to S&P 500 or RUSSELL 2000 index.

  • RUSSELL 2000
  • Others
  • S&P 500
Index%
RUSSELL 200055.1
Others28.2
S&P 50016.7
Top 5 Winners (%)%
alumis inc.
97.9 %
dianthus therapeutics, inc.
96.2 %
enliven therapeutics, inc.
65.2 %
CNTA
centessa pharmaceuticals plc
58.8 %
AGLE
spyre therapeutics, inc.
54.0 %
Top 5 Winners ($)$
KOD
kodiak sciences inc.
202.4 M
RVMD
revolution medicines, inc.
167.3 M
CELC
celcuity inc.
114.0 M
ALKS
alkermes plc
73.9 M
SMMT
summit therapeutics inc.
53.5 M
Top 5 Losers (%)%
WVE
wave life sciences ltd.
-48.8 %
VRDN
viridian therapeutics, inc.
-37.1 %
BCYC
bicycle therapeutics plc
-34.5 %
grail, inc.
-33.2 %
SERA
sera prognostics, inc.
-31.2 %
Top 5 Losers ($)$
ACAD
acadia pharmaceuticals inc.
-190.9 M
INCY
incyte corporation
-143.0 M
MDGL
madrigal pharmaceuticals, inc.
-126.1 M
RYTM
rhythm pharmaceuticals, inc.
-112.5 M
grail, inc.
-103.7 M

Felix & Julian Baker Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of Felix & Julian Baker

BAKER BROS. ADVISORS LP has 83 stocks in it's portfolio. About 73.5% of the portfolio is in top 10 stocks. ACAD proved to be the most loss making stock for the portfolio. KOD was the most profitable stock for BAKER BROS. ADVISORS LP last quarter.

$17.42BTotal Value
93.00Positions
15 May, 2026Last Reported
Current holdings of Current Stock Holdings of Felix & Julian Baker, last reported on 15 May, 2026. Select a row with a linked ticker to view its historical trend.
ExpandHoldingsorted ascending% PortfolioShares Held$ Value% Change
ARGX
Argenx Se

Argenx Se

ARGX
Felix & Julian Baker's holding in Argenx Se over time
0.11%25,174
$18.38M
0.11%
unchanged 0 percentunchanged
BNTX
Biontech Se

Biontech Se

BNTX
Felix & Julian Baker's holding in Biontech Se over time
0.06%119,743
$10.64M
0.06%
decreased 67.54 percentreduced
CMPS
Compass Pathways Plc

Compass Pathways Plc

CMPS
Felix & Julian Baker's holding in Compass Pathways Plc over time
0.07%2,344,720
$12.97M
0.07%
new position